Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 3 (2006), Issue 10 (October)

1. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
   Int J Gynecol Cancer, 16(5): 1897-902. [Abstract] [Full-text]
2. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
   Br J Cancer, 95(7): 788-93. [Abstract] [Full-text]
3. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.
   Mol Cancer Ther, 5(10): 2572-9. [Abstract] [Full-text]
4. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
   Mol Pharmacol, 70(5): 1534-41. [Abstract] [Full-text]
5. erbB2 is required for G protein-coupled receptor signaling in the heart.
   Proc Natl Acad Sci U S A, 103(43): 15889-93. [Abstract] [Full-text]
6. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers.
   Clin Cancer Res, 12(20): 6179-85. [Abstract] [Full-text]
7. Metastatic breast cancer: an updating.
   Biomed Pharmacother, 60(9): 548-56. [Abstract] [Full-text]
8. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes.
   J Mol Cell Cardiol, 41(5): 845-54. [Abstract] [Full-text]

© 2004-2010 Herceptin Research Today. All Rights Reserved.